経歴
L.-C. Campeau obtained his Ph. D. degree in 2007 with the late Professor Keith Fagnou at the University of Ottawa in Canada. He first joined Merck Research Laboratories at Merck-Frosst in Montreal in 2007 where he was recognized for key contributions to the discovery of doravirine (DELSTRIGO & PIFELTRO) a next generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. In 2010, he moved from Quebec to New Jersey, where he has served in roles of increasing responsibility. L.-C. is currently Associate Vice President and the Head of Small Molecule Process Research and Development. Over his tenure at Merck, L.-C. and his team have made important contributions to >60 clinical candidates and 8 commercial products including the recently approved LIPFENDRA, the first approved oral PSCK9 inhibitor, for which he co-led the early development team. Under his leadership, his organization was recognized with 5 EPA Green Chemistry Challenge Award and 2 Heroes of Chemistry Award. His passion for scientific excellence is exemplified by >95 publications and patents, and >100 invited lectures worldwide. L.-C. is a Fellow of the American Chemical Society (2026) and was elected Fellow of the Royal Society of Canada in 2022.